<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma	</title>
	<atom:link href="https://www.novumpr.nl/2017/10/16/ipsen-announces-that-phase-3-celestial-trial-of-cabozantinib-meets-primary-endpoint-of-overall-survival-in-patients-with-advanced-hepatocellular-carcinoma/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.novumpr.nl/2017/10/16/ipsen-announces-that-phase-3-celestial-trial-of-cabozantinib-meets-primary-endpoint-of-overall-survival-in-patients-with-advanced-hepatocellular-carcinoma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ipsen-announces-that-phase-3-celestial-trial-of-cabozantinib-meets-primary-endpoint-of-overall-survival-in-patients-with-advanced-hepatocellular-carcinoma</link>
	<description>NovumPR press releases</description>
	<lastBuildDate>Mon, 16 Oct 2017 11:42:21 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.3</generator>
</channel>
</rss>
